Joint meeting ADWP & SAAWP November 2016, Paris, France
|
|
- Tyrone Powell
- 6 years ago
- Views:
Transcription
1 ,
2 Preliminary Programme 09 November - ADWP Educational 10:00-10:30 Welcome & coffee 1 st session Connective tissue diseases Chair: David Kiely & Renate Arnold 10:30-10:50 How do we make HSCT for SSc safer? EBMT Guidelines Dominique Farge 10:50-11:10 Immune reconstitution and mechanistic aspects Maria-Carolina Oliveira 11:10-11:30 Gene and cell therapies for systemic autoimmune diseases Attilio Bondanza 11:30-11:50 Future protocols and trials in SSc and SLE. Tobias Alexander 2 nd session Crohn s session Chair: John Snowden & Elena Ricart 11:50-12:10 CD guidelines/current recommendations Montserrat Rovira 12:10-12:30 Immune reconstitution in Crohn s disease TBA 12:30-12:50 What comes after ASTIC/ what next trial TBA 12:50-13:00 EBMT data on Crohn s disease Cristina Castilla Llorante Charlotte Brieley 13:00-14:00 Lunch
3 3 rd session Neurological diseases Chair: Paolo Muraro & Hans Hagglund 14:00-14:20 Choice of patient in MS Basil Sharrack 14:20-14:40 Choice of conditioning regimen in MS Riccardo Saccardi 14:40-15:00 Chronic inflammatory demyelinating polyneuropathy (CIDP) Joachim Burman 15:00-15:30 Canadian experience for ASCT in Multiple Sclerosis, Myasthenia Gravis, and Stiff Person Syndrome Harold Atkins 15:30-16:00 Coffee break 4 th session Rare indications Chair: Tobias Alexander & Majid Kazmi 16:00-16:20 Vasculitis and Polymyositis/Dermatomyositis Thomas Daikeler 16:20-16:40 HSCT and Cellular Therapy in immune cytopenia Nicola Cooper 16:40-17:00 HSCT for autoinflammatory paediatric diseases Mario Abinun 17:00-17:20 Close and Discussion
4 10 November - Business meetings 08:30-10:30 Business meetings 10:30-10:45 Coffee break 10:45-12:30 Joint Educational session 5 th session Conditioning regimens and post-transplant care Chair: John Snowden & Regis Peffault de Latour 10:45-11:05 New conditioning regimens what can the ADWP and the SAAWP learn from each other? Jakob Passweg 11:05-11:25 Vaccinations in aplastic anaemia and autoimmune diseases Per Ljungman 11:25-11:35 Secondary autoimmune diseases following HSCT Paul Miller 6 th session ATG Chair: Carlo Dufour & Tobias Alexander 11:35-11:55 Mechanism of Action Phillip Scheinberg 11:55-12:15 Role of ATG in RIC Fabio Ciceri 12:15-12:35 Overlap Syndromes Maurizio Miano 12:45-14:00 Lunch
5 10 November - SAAWP Educational 14:00-14:15 Opening Carlo Dufour, Regis Peffault de Latour 7 th session Chair: Carlo Dufour, Regis Peffault de Latour 14:15-14:45 Physiopathology of idiopathic aplastic anemia Shahram Kordasti 14:45-15:00 Questions Controversy I: Do I consider somatic mutations in AA as MDS? Chair: Shahram Kordasti 15:00-15:15 Yes Austin Kulasekararaj 15:15-15:30 No Gérard Socié 15:30-16:00 Debate 16:00-16:30 Coffee break 8 th session Chair: Gérard Socié 16:30-17:00 First line treatment Judith Marsh 17:00-17:15 Questions
6 Controversy II: Do I offer transplantation for young patients (<20 years) with classic PNH and a matched available sibling donor? Chair: Antonio Risitano 17:15-17:30 Yes Hubert Schrezenmeier 17:30-17:45 No Regis Peffault de Latour 17:45-18:15 Debate 19:30-23:00 Social Event 11 November - SAAWP Educational 9 th session Chair: Marc Bierings 08:00-08:30 MUD transplant for AA. Where we come from, where we are, where we go Jakob Passweg 08:30-08:45 Questions Controversy III: Do I offer upfront MUD in children with aplastic anemia? Chair: Judith Marsh 08:45-09:00 Yes Carlo Dufour 09:00-09:15 No Philip Scheinberg 09:15-09:45 Debate 09:45-10:15 Coffee break
7 10 th session Chair: Mahmoud Aljurf 10:15-10:45 Refractory AA patients: place and management of Eltrombopag Antonio Risitano 10:45-11:00 Questions Controversy IV: What is the best salvage transplantation approach for refractory AA? Chair: Andre Tichelli 11:00-11:15 CBT Regis Peffault de Latour 11:15-11:30 Haplo Jakob Passweg 11:30-12:00 Debate 12:00-13:00 Lunch 11 th session Chair: Andre Tichelli 13:00-13:30 Telomere disease Rodrigo Calado 13:30-13:45 Questions Controversy V: Transplant for telomeropathy? Chair: Alicia Rovo 13:45-14:00 Yes Jean Hugues Dalle 14:00-14:15 No Danielle Townsley 14:15-14:45 Debate 14:45-15:15 Coffee break
8 12 th session Chair: Francesca Fioredda & Jean Soulier 15:15-15:45 Clonal evolution in FA patients: all go to transplantation? Jean Soulier 15:45-16:00 Questions 16:00-16:30 Severe congenital neutropenia: anything new? Francesca Fioredda 16:30-16:45 Questions 16:45-17:15 Closing Remarks
Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples
4ème Journée Nationale Maladies Rares Immuno-Hématologiques Paris, June 7th 2018 Matched unrelated upfront transplantation in idiopathic aplastic anemia? Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone
More informationLatest results of sibling HSCT in acquired AA. Jakob R Passweg
Latest results of sibling HSCT in acquired AA Jakob R Passweg Impact on Outcome: Patient Age, Disease Severity Title: Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biological and
More informationEBMT ADWP/IEWP. 3 rd 5 th November 2017 Newcastle, UK IEWP Chairman: A Lankester IEWP Secretary: M Albert. Local Chair: A Gennery
EBMT ADWP/IEWP 3 rd 5 th November 2017 Newcastle, UK IEWP Chairman: A Lankester IEWP Secretary: M Albert ADWP Chairman: J Snowden ADWP Secretary: T Alexander Local Chair: A Gennery Telephone: +44 (0)191
More informationOUTCOME AFTER IMMUNOSUPPRESSION
OUTCOME AFTER IMMUNOSUPPRESSION EBMT Aplastic Anemia Educational Meeting Budapest November 1 st 2012 Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplant Unit Hematology, DBBM Federico II University
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationSevere Aplastic Anemia in Children and Adolescents. Brigitte Strahm 21. April 2018
Severe Aplastic Anemia in Children and Adolescents Brigitte Strahm 21. April 2018 Acquired Aplastic Anemia in children What is aquired aplastic anemia? Camitta, Blood 1976 How A.L.G. acts is unknown, but
More informationDisclosers Updates: Management of Aplastic Anemia and Congenital Marrow Failure 5/9/2017
2017 Updates: Management of Aplastic Anemia and Congenital Marrow Failure Sachit Patel, MD Department of Pediatrics Division of Hematology-Oncology Blood and Marrow Transplantation Disclosers None 1 Objectives:
More informationIncrease the level of science across the organization with a view to advancing clinical practice;
Annual Report Annual Report Table of Contents Introduction to the EBMT 4 2012 EBMT at a glance 5 Foreword by the EBMT President 6 Highlights of 2013 Strategic Plan by the EBMT Executive Director 7 Feature
More informationAAMDSIF. Aplastic Anemia Research Summary from the DIAGNOSIS RTEL1 Mutations and Bone Marrow Failure
AAMDSIF Aplastic Anemia Research Summary from the 2016 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING A Summary of Selected Scientific Abstracts for Patients with Aplastic Anemia and Their Caregivers DIAGNOSIS
More informationAplastic Anaemia Genomics: Current data and interpretation
An Academic Health Sciences Centre at the heart of a world city... Aplastic Anaemia Genomics: Current data and interpretation Austin G Kulasekararaj Consultant Haematologist King s College Hospital, London
More informationUnrelated allogeneic transplantation for severe aplastic anemia is a treatment
ARTICLE Stem Cell Transplantation EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society
More informationTransplantation for bone marrow failure: current issues
BONE MARROW FAILURES Transplantation for bone marrow failure: current issues Régis Peffault de Latour Service d Hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), Paris,
More informationShall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD
Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de
More information7/12/2016 TESTING. Objectives. New Directions in Aplastic Anemia: What's on the Horizon? Better way to evaluate clonal evolution?
New Directions in Aplastic Anemia: What's on the Horizon? Amy E. DeZern, MD; MHS Assistant Professor Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, MD Objectives
More information(EWOG-MDS/SAA) International Meeting on Childhood MDS and SAA 28 30SEPTEMBER2017. ROMA EVENTI FONTANA DI TREVI Piazza della Pilotta - Roma
International Meeting on Childhood MDS and SAA (EWOG-MDS/SAA) ROMA EVENTI FONTANA DI TREVI Piazza della Pilotta - Roma 28 30SEPTEMBER2017 President of the meeting: Prof. Franco Locatelli Scientific committee:
More informationPacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO!
Pacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO! Phillip Scheinberg, MD Head, Clinical Hematology Hospital A Beneficência Portuguesa de Sao Paulo
More informationClinical significance of acquired somatic mutations in aplastic anaemia
Int J Hematol (2016) 104:159 167 DOI 10.1007/s12185-016-1972-8 PROGRESS IN HEMATOLOGY Recent advance in the diagnosis and treatment of bone marrow failure syndromes Clinical significance of acquired somatic
More informationAplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood
What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood
More informationAplastic Anemia: Fill Er Up! But With What? Speaker s Disclosure Statement. Objectives. Aplastic Anemia: Fill Er Up? But With What?
Fill Er Up! But With What? Karyn Brundige, MSN, CPNP Dana-Farber/Boston Children s Cancer and Blood Disorders Center karyn.brundige@childrens.harvard.edu Speaker s Disclosure Statement I have no industry
More informationEducational Sessions The transplant algorithm in lymphoma (1E) P. Dreger M. Gomes da Silva N. Milpied S. Montoto A. Sureda
Educational Sessions The transplant algorithm in lymphoma (1E) Chairs: P. Dreger, Germany; M. Gomes da Silva, Portugal o High grade lymphoma: N. Milpied, France o Role of stem cell transplantation in patients
More informationIntroduction. Helen Jessop 1. Dominique Farge 2,3,4,5. Riccardo Saccardi 6. Tobias Alexander 7. Montserrat Rovira 8 Basil Sharrack 9.
Bone Marrow Transplantation https://doi.org/10.1038/s41409-019-0430-7 PERSPECTIVE General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune
More informationOverview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
More informationresearch paper Summary
research paper Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant Summary This
More informationImmunosuppressive treatment in acquired aplastic anemia. André Tichelli Hematology, University Hospital Basel
Immunosuppressive treatment in acquired aplastic anemia André Tichelli Hematology, University Hospital Basel Why is immunosuppressive treatment a choice for acquired aplastic anemia? Hematopoietic stem
More informationThe function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018
The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry
More informationEvidence from bone marrow transplantation
Evidence from bone marrow transplantation Gianluigi Mancardi Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Ospedale Policlinico San Martino, University
More informationAUTOLOGOUS STEM CELL TRANSPLANTATION for AUTOIMMUNE DISEASES? YES
AUTOLOGOUS STEM CELL TRANSPLANTATION for AUTOIMMUNE DISEASES? YES Pr Dominique Farge, Hôpital St Louis, Paris 7 Denis Diderot University, France, ADWP EBMT Chair The European Group for Blood and Marrow
More informationAplastic Anemia: Understanding your Disease and Treatment Options
Aplastic Anemia: Understanding your Disease and Treatment Options No financial relationships or commercial interest related to the content of this presentation Josh Sasine, MD, PhD Hematopoietic Cell Transplant
More informationAplastic anemia: therapeutic updates in immunosuppression and transplantation
IMMUNE DYSREGULATION Aplastic anemia: therapeutic updates in immunosuppression and transplantation Phillip Scheinberg 1 1 Hematology Branch, National Heart, Lung and Blood Institute, National Institutes
More informationAplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment
7/23/212 Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment Danielle Townsley, MD, MSc Hematology Branch National, Heart, Lung and Blood Institute National Institutes
More informationHematopoietic Cell Transplantation for Autoimmune Diseases
Medical Policy Manual Transplant, Policy No. 45.32 Hematopoietic Cell Transplantation for Autoimmune Diseases Next Review: April 2018 Last Review: December 2017 Effective: January 1, 2018 IMPORTANT REMINDER
More informationTarget audience. Chair. Xxx Xxx
STUDENTS FOR FREE EXCEMED WORKSHOP The immunomodulatory role of therapeutic plasma exchange in neuromuscular and PNS diseases: a practical approach & new knowledge London, UK - 19 May 2018 The immunomodulatory
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationAplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment
4/18/212 Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment Bogdan Dumitriu, MD Hematology Branch National, Heart, Lung and Blood Institute National Institutes of Health
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: July 09, 2018 Report Length: 7 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Eltrombopag for the treatment of Aplastic Anemia: A Review of Clinical and Cost-Effectiveness Service Line: Rapid Response Service Version:
More informationOutline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options
Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases
More informationManagement of acquired aplastic anemia in children
Management of acquired aplastic anemia in children Korthof, E. T.; Békássy, Albert; Hussein, A. A. Published in: Bone Marrow Transplantation DOI: 10.1038/bmt.2012.235 Published: 2013-01-01 Link to publication
More informationARTICLES. Introduction
ARTICLES Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic
More informationClonality & Aplastic anemia / PNH
Clonality & Aplastic anemia / PNH What is in a word W Shakespear : Hamlet Prof G SOCIE, MD, PhD Head Division of Hematology / Immunology / Oncology French reference Center Aplastic Anemia & PNH Hospital
More informationComment devenir CCA en un WE? HPN aplasie médullaire
Comment devenir CCA en un WE? HPN aplasie médullaire Régis Peffault de Latour, MD, PhD Saint Louis Hospital, Paris; regis.peffaultdelatour@sls.aphp.fr AIH 27 Septembre 2014 Paroxysmal Nocturnal Hemoglobinuria
More informationSixth International Bone Marrow Failure Disease Scientific Symposium. Collaborating to Transform Treatment and Improve Outcomes. Summary for Patients
Sixth International Bone Marrow Failure Disease Scientific Symposium Collaborating to Transform Treatment and Improve Outcomes Summary for Patients AAMDSIF would like to thank the corporations whose generous
More informationStem-Cell Transplantation for Autoimmune Diseases/Miscellaneous Conditions
Medical Coverage Policy Effective Date...09/15/2017 Next Review Date...09/15/2018 Coverage Policy Number... 0357 Stem-Cell Transplantation for Autoimmune Diseases/Miscellaneous Conditions Table of Contents
More informationAplastic Anemia Pathophysiology and Approach to Therapy
Aplastic Anemia Pathophysiology and Approach to Therapy BSMCON 2018 Dr. Syed Ghulam Mogni Mowla MBBS, FCPS, FACP Introduction Aplastic anaemia (AA) is the paradigm of the human bone marrow failure syndromes
More informationBone Marrow Transplantation in Neurological Disease
Bone Marrow Transplantation in Neurological Disease Dr. Mark S. Freedman MSc MD FAAN FANA CSPQ FRCPC Professor or Neurology University of Ottawa Sr. Scientist, The Ottawa Hospital Research Institute Ottawa,
More information18 th EULAR Postgraduate Course
18 th EULAR Postgraduate Course Belgrade, Serbia 22 25 October 2017 eular.org ORGANISATION AND COMMITTEE Scientific organiser Professor, Serbia Chairperson EULAR standing Committee on Education and Training
More informationTarget audience. Chair. Xxx Xxx
EXCEMED WORKSHOP The immunomodulatory role of therapeutic plasma exchange in neuromuscular and PNS diseases: a practical approach & new knowledge London, UK - 19 May 2018 The immunomodulatory role of therapeutic
More informationEltrombopag Added to Standard Immunosuppression for Aplastic Anemia
The new england journal of medicine Original Article Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Danielle M. Townsley, M.D., Phillip Scheinberg, M.D., Thomas Winkler, M.D., Ronan
More informationNontransplant therapy for bone marrow failure
Nontransplant therapy for bone marrow failure Danielle M. Townsley and Thomas Winkler BONE MARROW FAILURES Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD Nontransplant therapeutic
More informationHematopoietic Stem Cell Transplantation for Autoimmune Diseases
Protocol Hematopoietic Stem Cell Transplantation for Autoimmune Diseases (80125) Medical Benefit Effective Date: 04/01/14 Next Review Date: 11/17 Preauthorization Yes Review Dates: 04/07, 05/08, 01/10,
More informationImmunotherapies for aplastic anemia
Workshop on Hematology and Bone Marrow Transplant May 11 12, 2018, São Paulo Immunotherapies for aplastic anemia Diego Villa Clé, MD, PhD Attending Physician Hospital das Clínicas Faculdade de Medicina
More informationa SAA-WP trial RACE study Sponsor Protocol Number: EudraCT TrialNumber: Coordinating Investigators:
A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hatg) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients. RACE
More informationTransplants and T Cells: New Solutions for Old Problems?
Transplants and T Cells: New Solutions for Old Problems? Tuesday 25 th September 2018 Crowne Plaza Hotel City Centre Wollaton Street, Nottingham NG1 5RH Welcome Welcome to Nottingham! The field of immunotherapy
More informationSevere Chronic Neutropenia
Haematopoietic Stem Cell Transplantation Severe Chronic Neutropenia F. Fioredda Unit of Haematology Giannina Gaslini Children s Hospital No disclosures Severe Chronic Neutropenia Persistence above 6 months
More informationHow I treat acquired aplastic anemia
How I treat acquired aplastic anemia Phillip Scheinberg and Neal S. Young Blood Volume 120(6):1185-1196 August 9, 2012 2012 by American Society of Hematology Symptoms, Signs, and Lab Findings Bruising,
More informationInternational Meeting dedicated to the memory of Raisa Gorbacheva. HEMOPOIETIC STEM CELLS TRANSPLANTATION Saint-Petersburg, September 21-22, 2007
International Meeting dedicated to the memory of Raisa Gorbacheva HEMOPOIETIC STEM CELLS TRANSPLANTATION Saint-Petersburg, September 21-22, 2007 Preliminary program September 21 Friday 8.00-8.30 - registration
More informationHematopoietic Stem Cell Transfusion for Autoimmune diseases Clínica Ruiz
Hematopoietic Stem Cell Transfusion for Autoimmune diseases Clínica Ruiz Background: Since 1993, scientists from the Centro de Hematología y Medicina Interna de Puebla (CHMI) have engaged in practicing
More information4nd Patient and Family Day
4nd Patient and Family Day EBMT Slide template Barcelona 7 February 2008 EBMT 2010 Vienna, Austria ; www.ebmt.org History of Stem Cell Transplantation Appelbaum et al, NEJM 2006 What is EBMT? Scientific,
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More informationArLAR 2018, the Pan Arab Rheumatology Conference in conjunction with the 1st OSR meeting 23 to 25 February 2018, Muscat, Oman.
ArLAR 2018, the Pan Arab Rheumatology Conference in conjunction with the 1st OSR meeting 23 to 25 February 2018, Muscat, Oman. to change at any time www.arlar.org info@arlar.org #ArLAR2018 Thursday, 22
More information4/3/2013. First Risk Stratification: Rule out Inherited Marrow Failure Disease
Improved Outcome Following Unrelated Donor Allografts: When Should BMT Be Considered for Adults and Children with Severe Aplastic Anemia? Michael Pulsipher, MD Professor Of Pediatrics/Internal Medicine
More information3 rd EBMT International Transplant Course
3 rd EBMT International Transplant Course 07 th 9 th September 2018, University of Barcelona, Faculty of Medicine Carrer de Casanova 143, 08036 Barcelona, Spain #EBMTITC18 EBMT International WELCOME It
More informationCurrent Status of Haploidentical Hematopoietic Stem Cell Transplantation
Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT
More informationLate Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy): Follow up of a Randomized Trial
Blood First Edition Paper, prepublished online June 28, 2002; DOI 10.1182/blood-2002-02-0494 Late Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy):
More information18 th EULAR Postgraduate Course
18 th EULAR Postgraduate Course Belgrade, Serbia 22 25 October 2017 eular.org ORGANISATION AND COMMITTEE Scientific organiser Professor, Serbia Chairperson EULAR standing Committee on Education and Training
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to: Alexion Pharmaceuticals
More informationNot So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Robert A. Brodsky, MD Johns Hopkins Family Professor
More informationAllogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
More informationBor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital
Bor-Sheng Ko Hematology Division, Department of Internal Medicine, National Taiwan University Hospital On behalf of Members of Aplastic Anemia Consensus Meeting Diagnosis and classification: Treatment
More informationArticles and Brief Reports
Articles and Brief Reports Stem Cell Transplantation Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin
More informationVersion 1.11 of 20/07/2018
Version 1.11 of 20/07/2018 NICE JANUARY 17-19, 2019 6 th International Workshop on Lung Health New approaches to respiratory diseases PRESIDENTS: F. BLASI, G.W. CANONICA CHAIRMEN: S. CENTANNI, J.C. VIRCHOW,
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationReporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation
Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation Marcelo C. Pasquini, MD, MSc HVD05_1.ppt Outline Review of autoimmune diseases (AID). Role of transplantation for AID Data collection:
More informationMonday, March 27th 16:30-18:00. Oral 6: Autoimmune diseases and solid tumors
Monday, March 27th 16:30-18:00 Oral 6: Autoimmune diseases and solid tumors Outcome of autologous non-myeloablative hematopoietic stem cell transplantation in patients with refractory Chronic Inflammatory
More informationObjectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia
SAA 101: An Introductory Course to Severe Aplastic Anemia David A. Margolis, MD Professor of Pediatrics/Medical College of Wisconsin Program Director/ Children s Hospital of Wisconsin BMT Program Objectives
More informationAnnual Conference of the Canadian Blood and Marrow Transplant Group. June 11 to 14, 2014 The Westin Nova Scotian 1181 Hollis Street Halifax, NS
Annual Conference of the Canadian Blood Preliminary Program In conjunction with the Canadian National, Canadian Apheresis Group, Society, and Vector CBMTG Head Office Malachite Management Inc 375 West
More informationHow I manage aplastic anaemia in children
state of the art review How I manage aplastic anaemia in children Sujith Samarasinghe 1 and David K. H. Webb 2 1 Paediatric Haematopoietic Stem Cell Transplant Unit, Department of Adolescent and Paediatric
More information9/9/2015 HISTORY & EPIDEMIOLOGY. Objectives. Textbook Definition of Aplastic anemia (AA) Epidemiology. History
Objectives Aplastic Anemia: Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Amy E. DeZern, MD, MHS Assistant Professor of Oncology and Medicine The Johns Hopkins University School
More informationClinical Policy Title: Stem cell transplants for autoimmune disease
Clinical Policy Title: Stem cell transplants for autoimmune disease Clinical Policy Number: 18.03.02 Effective Date: April 1, 2016 Initial Review Date: June 16, 2013 Most Recent Review Date: January 18,
More informationIVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following documented indications: 1. Primary Immunodeficiency Disease (PID) with ONE of the a. Hypogammaglobulinemia,
More informationREPORT. KEY WORDS: Severe aplastic anemia, Blood and marrow transplantation, Immunosuppressive therapy, Telomeres
REPORT Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biologic, and Treatment Response Parameters: Conclusions of an International Working Group on Severe Aplastic Anemia Convened
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Autoimmune Diseases File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_autoimmune_diseases
More informationManagement of acquired aplastic anemia in children
Bone Marrow Transplantation (2013) 48, 191 195 & 2013 Macmillan Publishers Limited All rights reserved 0268-3369/13 www.nature.com/bmt REVIEW Management of acquired aplastic anemia in children ET Korthof
More informationLong-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin
Published Ahead of Print on July 13, 2017, as doi:10.3324/haematol.2017.171215. Copyright 2017 Ferrata Storti Foundation. Long-term risk of cancer development in adult patients with idiopathic aplastic
More informationAllogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009
(2010) 45, 219 234 & 2010 Macmillan Publishers Limited All rights reserved 0268-3369/10 $32.00 www.nature.com/bmt SPECIAL REPORT Allogeneic and autologous transplantation for haematological diseases, solid
More informationAplastic Anemia: Management of Adult Patients
Aplastic Anemia: Management of Adult Patients Jaroslaw P. Maciejewski and Antonio M. Risitano The primary therapeutic approach to acquired aplastic anemia (AA) in older adults differs from the primary
More informationMaking Therapeutic Decisions in Adults with Aplastic Anemia
Making Therapeutic Decisions in Adults with Aplastic Anemia Judith Marsh The management of adults presenting with aplastic anemia (AA) requires careful exclusion of other causes of bone marrow failure.
More informationHSCT - Minimum Essential Data - A REGISTRATION - DAY 0
CIC: HSCT - Minimum Essential Data - A REGISTRATION - DAY 0 Centre Identification EBMT Code (CIC): Contact person: Hospital: Email: Unit: Patient Data Date of this report: First transplant for this patient?:
More informationImmunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC Experience
36 supplement to Journal of the association of physicians of india Published on 1st of every month 1st march, 2015 Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC
More informationBREAKS NETWORKING EVENTS PARALLEL SESSIONS INDUSTRY SUPPORTED SESSIONS Academy of Autoimmunity SYMPOSIUM
PLENARY SESSIONS BREAKS NETWORKING EVENTS PARALLEL SESSIONS INDUSTRY SUPPORTED SESSIONS SYMPOSIUM Monday, 14 May 2018 13:00-15:30 15:30 16:00 COFFEE BREAK 16:00-17:30 Tuesday, 15 May 2018 08:00-08:30 08:30-10:30
More informationInt J Clin Exp Med 2015;8(9): /ISSN: /IJCEM
Int J Clin Exp Med 2015;8(9):16334-16339 www.ijcem.com /ISSN:1940-5901/IJCEM0011065 Original Article Not all anti-t lymphocyte globulin preparations are suitable for use in aplastic anemia: significantly
More informationClinical Policy Title: Stem cell transplants for autoimmune disease
Clinical Policy Title: Stem cell transplants for autoimmune disease Clinical Policy Number: 18.03.02 Effective Date: April 1, 2016 Initial Review Date: June 16, 2013 Most Recent Review Date: January 11,
More informationFirst line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated
Received: 30 January 2018 Revised: 24 February 2018 Accepted: 26 February 2018 DOI: 10.1002/ajh.25081 RESEARCH ARTICLE First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome
More informationPNH from the perspective of Paediatric Haematologists
EBMT Severe Aplastic Anaemia and Infectious Diseases Working Parties Bruno Rotoli Memorial Educational Course 29 Sept 1 Oct 2014 PNH from the perspective of Paediatric Haematologists Fabio Timeus, MD PhD
More informationHSCT - Minimum Essential Data - A REGISTRATION - DAY 0
HSCT - Minimum Essential Data - A REGISTRATION - DAY 0 Centre Identification EBMT Code (CIC): Contact person: Hospital: Email: Unit: Patient Data Date of this report: First transplant for this patient?:
More informationHSCT - Minimum Essential Data - A REGISTRATION - DAY 0
HSCT - Minimum Essential Data - A REGISTRATION - DAY 0 Centre Identification EBMT Code (CIC): Contact person: Hospital: Email: Unit: Patient Data Date of this report: First transplant for this patient?:
More informationFungal infections. Ematologia. Corrado Girmenia. Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy
Fungal infections Corrado Girmenia Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy Ematologia Epidemiology Diagnostic approach Prevention strategies Monitoring of IFDs in
More informationHaploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia
Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal
More informationAndrew Schorr: Dr. Young, for patients receiving initial treatment could you discuss the findings comparing horse ATG and rabbit ATG?
What s New in Aplastic Anemia Treatment American Society of Hematology Meeting December 2011 Dr. Neal S. Young Please remember the opinions expressed on Patient Power are not necessarily the views of our
More informationSTEP BY STEP. Aplastic Anaemia
STEP BY STEP Aplastic Anaemia Introduction Being diagnosed with aplastic anaemia (AA) can be a shock, particularly when you may have never heard of it. If you have questions about AA, what causes it, who
More informationAplastic Anemia: Current Thinking
Aplastic Anemia: Current Thinking ANDREW C. DIETZ, MD, MSCR PEDIATRIC BLOOD AND MARROW TRANSPLANTATION CHILDREN S HOSPITAL LOS ANGELES, UNIVERSITY OF SOUTHERN CALIFORNIA Outline Ø What is Aplastic Anemia?
More information